ATB Therapeutics Raises €54 Million Series A Financing to Propel Innovative Antibody Payload Technology into Clinical Development

ATB Therapeutics is dedicated to pioneering First-in-Class biologics that incorporate novel cell- killing mechanisms, including enzymatic functionalities within targeted antibodies. These rapidly produced heterobifunctional antibodies combine multiple targeting and killing domains, enhancing their effectiveness and safety compared to traditional conjugates. The ATBioFarm technology facilitates the scalable, single-step production of these sophisticated, highly stable and homogenous biologics, promising significant advancements across various therapeutic applications.

The current capital increase will allow ATB to expand and enhance its state-of-the-art ATBioFarm platform as well as to accelerate development of its unique "weaponized" antibodies for oncology and immunology applications. ATB's research and development operations will be extended to Ghent and will continue in Marche-en-Famenne, where the Company is also setting up a cutting- edge pilot manufacturing facility.

In conjunction with this funding, ATB is excited to announce the appointment of Mark Throsby as Executive Chairman. Mark is an industry veteran and the former Chief Scientific Officer of Merus (NASDAQ: MRUS) where he was instrumental in the development of the bispecific antibody therapeutics petosemtamab and zenocutuzumab. With his wealth of experience and expertise in antibody development, Mark further strengthens the Company's leadership, as ATB embarks on this pivotal phase of growth. The Company is also welcoming seasoned biotech investors Karin Kleinhans, Partner at MRLV, and John de Koning, Partner at EQT, to its Board of Directors.

“Our successful financing round demonstrates the strong potential of the ATBioFarm platform and the confidence prominent international investors have in our vision,” stated Bertrand Magy, CEO and co-founder of ATB Therapeutics. “We are grateful to our existing investors and the Région Wallonne for their unwavering support. This funding will enable us to bolster our team, expand our operations, and advance our mission to deliver transformative therapies to patients worldwide.”

Mark Throsby expressed his enthusiasm for this new role, stating, “I am particularly impressed by the ATBioFarm platform’s capability to swiftly generate a diverse array of candidate molecules with unique cytotoxic and targeting features. This innovative approach addresses critical challenges in selecting ADC drug candidates and opens avenues for new mechanisms of action that fulfill unmet clinical needs. I look forward to collaborating with the ATB team to bring this vision to reality.”

“The founders of ATB Therapeutics have demonstrated remarkable entrepreneurial vision by establishing a proprietary drug discovery, development, and manufacturing platform from the ground up,” remarked John de Koning of EQT Life Sciences. “The platform's ability to manufacture antibodies from a single expression construct that integrates both targeting and direct cytotoxic functions is truly exceptional, positioning ATB as a prospective leader in the next generation of biopharmaceuticals. ”

“At MRLV, our mission is to identify and support innovative technologies capable of transforming treatment approaches and enhancing patient outcomes,” added Karin Kleinhans. "We are thrilled to collaborate with ATB Therapeutics as they advance a pioneering class of antibody therapeutics towards clinical development."